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Background
In the last years there is a great concern regarding the
effect of HIV and antiretroviral drugs in children born
by treated HIV-infected mothers.
We started a prospective cohort study regarding HIV
and antiretroviral exposure in children followed in the
Pediatric HIV Department from the National Institute
for Infectious Diseases “Prof. Dr. Matei Balş”, Bucharest.
Methods
We analyzed the data recorded for children perinatally-
exposed to HIV followed up in our Department from
January 1st 2006 to December 31st 2012. The patients were
followed up for 18 month after birth to establish the HIV
status; gestational age, birth defects and mother treatment
were noted.
Results
From 206 children with complete 18 months follow up,
21% (43 cases) were diagnosed with HIV infection and
more than 33% had at least one congenital condition.
We found birth defects in various organs in studied
children: heart (130 cases), musculoskeletal system
(47 cases), kidney (20 cases), nervous system (20 cases),
digestive tract (10 cases) and metabolic and genetic
disorders (2 cases each). 26 from the 163 HIV-exposed
children and 6 from the 43 HIV-infected cases were born
before 37 weeks of gestation, 4 HIV-exposed and 4
HIV-infected children were small for gestational age. We
found low birth weight (<2500 g) in 18 HIV-exposed
children and 3 HIV infected children and extremely low
birth weight (1000) in one HIV-exposed child.
We found congenital malformation in 11 preterm
HIV-exposed children and 2 preterm HIV-infected
children, but also in 38 HIV-exposed children and 19
HIV-infected babies with normal gestation period.
The difference between the rate of congenital malforma-
tion and prematurity was not statistically significant
(p=0.08) in any of studied groups and HIV diagnosis was
not associated with a higher risk of preterm birth (p=0.93).
Mother being part of the Romanian cohort was not statis-
tically associated with higher risk of prematurity.
We found a significant association between antiretroviral
treatment during pregnancy and prematurity (p=0.003).
The most used drugs to treat mothers were boosted
protease inhibitors (99% cases).
Conclusion
In the studied patients we found high risk of prematurity
in babies exposed in utero to antiretrovirals, but no asso-
ciation between prematurity and HIV infection in children
or mother being part of Romanian cohort.
Acknowledgement
This work is supported by the Sectorial Operational Programme Human
Resources Development financed from the European Social Found and by
Romanian Government under contract number POSDRU/159/1.5/S/137390.
Authors’ details
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
2National Institute for Infectious Diseases “Prof. Dr. Matei Balş”, Bucharest,
Romania. 3The Institute for Mother and Child Protection “Alfred Rusescu”,
Bucharest, Romania.
Published: 15 October 2014
doi:10.1186/1471-2334-14-S7-O9
Cite this article as: Tudor et al.: Antiretroviral treatment and association
with prematurity in perinatal HIV-exposed children. BMC Infectious
Diseases 2014 14(Suppl 7):O9.
* Correspondence: tudoranamaria@yahoo.com
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Full list of author information is available at the end of the article
Tudor et al. BMC Infectious Diseases 2014, 14(Suppl 7):O9
http://www.biomedcentral.com/1471-2334/14/S7/O9
© 2014 Tudor et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
